knowledge -WSS

knowledge

author：fashion 2025-08-12 13:35:00 - browse：16

Adobe

The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday.

The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees. And it opens the door for other Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses — even though many independent experts believe the quality rating system is flawed and doesn’t appropriately gauge quality of care for older adults and people with disabilities.

The Centers for Medicare and Medicaid Services, the federal agency that oversees all Medicare programs, said it does not comment on litigation. In an interview, SCAN CEO Sachin Jain told STAT that if the company had not gotten its expected bonus money, it would have had to shave benefits and reduce what it pays hospitals and doctors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： JPM: CVS says Medicare Advantage patients are impacting profits

WSS

Why the quest to eradicate polio has stumbled

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

White House Covid adviser calls on docs to combat misinformation

Patients, doctors press FTC to beef up hospital merger scrutiny

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

focus

Trump demands the U.S. pay no more for drugs than other countries … again

How a scoliosis diagnosis changed the life of one young dancer

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA panel to weigh safety of artificial wombs for preterm births

Hepatitis C has a cure — but many Americans still lack access to it

Morgan Health, with ambitious aims, wants you to know it’s still here

The cancer drug shortage isn’t new — and neither are the solutions

Senate bill would ban some hospital facility fees

Guidelines to prevent youth baseball injuries need more muscle

Neurocrine congenital adrenal hyperplasia trial succeeds

explore

The FDA must approve intranasal treatments for anaphylaxis

White House Covid adviser calls on docs to combat misinformation

Videos point to link between seizures and unexplained toddler deaths

JPM: CVS says Medicare Advantage patients are impacting profits

Videos point to link between seizures and unexplained toddler deaths

Burning questions for the 2024 JPM Healthcare Conference

leisure time

focus

Wikipedia

hotspot